Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;27(4):594-603.
doi: 10.1038/s41391-023-00676-0. Epub 2023 May 18.

Guidelines for genetic testing in prostate cancer: a scoping review

Haitham Tuffaha  1 , Kim Edmunds  2 , David Fairbairn  3 , Matthew J Roberts  4   5 , Suzanne Chambers  6 , David P Smith  7 , Lisa Horvath  8   9   10 , Shiksha Arora  2 , Paul Scuffham  11
Affiliations

Guidelines for genetic testing in prostate cancer: a scoping review

Haitham Tuffaha et al. Prostate Cancer Prostatic Dis. 2024 Dec.

Abstract

Background: Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relatives. There are various guidelines and consensus statements for genetic testing in prostate cancer. Our aim is to review genetic testing recommendations across current guidelines and consensus statements and the level of evidence supporting those recommendations.

Methods: A scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for scoping review (PRISMA-ScR) guidelines. Electronic database searches and manual searches of grey literature, including websites of key organisations were conducted. Using the Population, Concept, Context (PCC) framework, this scoping review included: men with prostate cancer or men at high risk of prostate cancer and their biological families; existing guidelines and consensus statements with supporting evidence for genetic testing of men with prostate cancer from any geographical location worldwide.

Results: Of the 660 citations identified, 23 guidelines and consensus statements met the inclusion criteria for the scoping review. Based on different levels of evidence about who should be tested and how, a diverse range of recommendations were identified. There was general consensus among the guidelines and consensus statements that men with metastatic disease be offered genetic testing; however, there was less consensus in relation to genetic testing in localised prostate cancer. While there was some consensus in relation to which genes to test, recommendations varied regarding who to test, testing methods and implementation.

Conclusion: While genetic testing in prostate cancer is routinely recommended and numerous guidelines exist, there is still considerable lack of consensus regarding who should be tested and how they should be tested. Further evidence is needed to inform value-based genetic testing strategies for implementation in practice.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. PRISMA diagram.
The stages of the literature search process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung HFJ, Siegel RL, Laversanne M, Soerjomatara I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clinicians. 2021;71:209–49. - PubMed
    1. Roehrborn C, Black L. The economic burden of prostate cancer. BJUI Int. 2011;108:806–13. - PubMed
    1. Kucera R, Pecen L, Topolcan O, Dahal A, Costigliola V, Girodano F, et al. Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions. EPMA J. 2020;11:399–418. - PMC - PubMed
    1. Australian Institute of Health and Welfare. Cancer data in Australia. Canberra: AIHW; 2022.
    1. Australian Institute of Health and Welfare. Health system expenditure on cancer and other neoplasms in Australia, 2015–16. Canberra: AIHW; 2021.

Publication types

MeSH terms